Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous cancer cells through the inhibitions of FAK, IKK, NF-κB, u-PA and MMP-2 and -9

Cancer Letters

Volumn 279, Issue 2, 2009, Pages 155-162

  Ho, Yung Tsuan ^a   Yang, Jai Sing ^a   Li, Tsai Chung ^a   Lin, Jen Jyh ^b   Lin, Jaung Geng ^a   Lai, Kuang Chi ^c   Ma, Chia Yu ^d   Wood, W Gibson ^e   Chung, Jing Gung ^a  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY BEIGANG HOSPITAL   (Taiwan)

^d TECHNOLOGY AND SCIENCE INSTITUTE OF NORTHERN TAIWAN   (Taiwan)

^e UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Berberine; Matrix metalloproteinases; Migration and invasion; SCC 4 cancer cells; Urokinase type plasminogen activator

Indexed keywords

BERBERINE; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE 1; GELATINASE A; GELATINASE B; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; UROKINASE RECEPTOR;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA; TONGUE SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BERBERINE; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; DOWN-REGULATION; FOCAL ADHESION KINASE 1; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; NF-KAPPA B; SIGNAL TRANSDUCTION; TONGUE NEOPLASMS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 67349103384     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.01.033     Document Type: Article

References (59)

1. Parkin D.M., Pisani P., and Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. International Journal of Cancer 80 (1999) 827-841
2. Hashibe M., Brennan P., Benhamou S., Castellsague X., Chen C., Curado M.P., Dal Maso L., Daudt A.W., Fabianova E., Fernandez L., Wunsch-Filho V., Franceschi S., Hayes R.B., Herrero R., Koifman S., La Vecchia C., Lazarus P., Levi F., Mates D., Matos E., Menezes A., Muscat J., Eluf-Neto J., Olshan A.F., Rudnai P., Schwartz S.M., Smith E., Sturgis E.M., Szeszenia-Dabrowska N., Talamini R., Wei Q., Winn D.M., Zaridze D., Zatonski W., Zhang Z.F., Berthiller J., and Boffetta P. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the international head and neck cancer epidemiology consortium. Journal of the National Cancer Institute 99 (2007) 777-789
3. Rahman M., Sakamoto J., and Fukui T. Calculation of population attributable risk for bidi smoking and oral cancer in south Asia. Preventive Medicine 40 (2005) 510-514
4. Balaram P., Sridhar H., Rajkumar T., Vaccarella S., Herrero R., Nandakumar A., Ravichandran K., Ramdas K., Sankaranarayanan R., Gajalakshmi V., Munoz N., and Franceschi S. Oral cancer in southern India: the influence of smoking, drinking, paan-chewing and oral hygiene. International Journal of Cancer 98 (2002) 440-445
5. Room R., Babor T., and Rehm J. Alcohol and public health. Lancet 365 (2005) 519-530
6. Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., Bouvard V., Altieri A., and Cogliano V. Carcinogenicity of alcoholic beverages. The Lancet Oncology 8 (2007) 292-293
7. Parkin D.M., and Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 24 suppl. 3 (2006) S11-S25
8. Applebaum K.M., Furniss C.S., Zeka A., Posner M.R., Smith J.F., Bryan J., Eisen E.A., Peters E.S., McClean M.D., and Kelsey K.T. Lack of association of alcohol and tobacco with HPV16-associated head and neck cancer. Journal of the National Cancer Institute 99 (2007) 1801-1810
9. Boccia S., Cadoni G., Sayed-Tabatabaei F.A., Volante M., Arzani D., De Lauretis A., Cattel C., Almadori G., van Duijn C.M., Paludetti G., and Ricciardi G. CYP1A1, CYP2E1, GSTM1, GSTT1, EPHX1 exons 3 and 4, and NAT2 polymorphisms, smoking, consumption of alcohol and fruit and vegetables and risk of head and neck cancer. Journal of Cancer Research and Clinical Oncology 134 (2008) 93-100
10. Schiller L.R. Review article: anti-diarrhoeal pharmacology and therapeutics. Alimentary Pharmacology & Therapeutics 9 (1995) 87-106
11. Hwang J.M., Kuo H.C., Tseng T.H., Liu J.Y., and Chu C.Y. Berberine induces apoptosis through a mitochondria/caspases pathway in human hepatoma cells. Archives of Toxicology 80 (2006) 62-73
12. Iizuka N., Miyamoto K., Okita K., Tangoku A., Hayashi H., Yosino S., Abe T., Morioka T., Hazama S., and Oka M. Inhibitory effect of Coptidis Rhizoma and berberine on the proliferation of human esophageal cancer cell lines. Cancer Letters 148 (2000) 19-25
13. Nishino H., Kitagawa K., Fujiki H., and Iwashima A. Berberine sulfate inhibits tumor-promoting activity of teleocidin in two-stage carcinogenesis on mouse skin. Oncology 43 (1986) 131-134
14. Peng P.L., Hsieh Y.S., Wang C.J., Hsu J.L., and Chou F.P. Inhibitory effect of berberine on the invasion of human lung cancer cells via decreased productions of urokinase-plasminogen activator and matrix metalloproteinase-2. Toxicology and Applied Pharmacology 214 (2006) 8-15
15. Fukuda K., Hibiya Y., Mutoh M., Koshiji M., Akao S., and Fujiwara H. Inhibition of activator protein 1 activity by berberine in human hepatoma cells. Planta Medica 65 (1999) 381-383
16. Fukuda K., Hibiya Y., Mutoh M., Koshiji M., Akao S., and Fujiwara H. Inhibition by berberine of cyclooxygenase-2 transcriptional activity in human colon cancer cells. Journal of Ethnopharmacology 66 (1999) 227-233
17. Kim S.A., Kwon Y., Kim J.H., Muller M.T., and Chung I.K. Induction of topoisomerase II-mediated DNA cleavage by a protoberberine alkaloid, berberrubine. Biochemistry 37 (1998) 16316-16324
18. Letasiova S., Jantova S., Cipak L., and Muckova M. Berberine-antiproliferative activity in vitro and induction of apoptosis/necrosis of the U937 and B16 cells. Cancer Letters 239 (2006) 254-262
19. Mantena S.K., Sharma S.D., and Katiyar S.K. Berberine inhibits growth, induces G1 arrest and apoptosis in human epidermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of mitochondrial membrane potential and cleavage of caspase 3 and PARP. Carcinogenesis 27 (2006) 2018-2027
20. Lin J.G., Chung J.G., Wu L.T., Chen G.W., Chang H.L., and Wang T.F. Effects of berberine on arylamine N-acetyltransferase activity in human colon tumor cells. The American Journal of Chinese Medicine 27 (1999) 265-275
21. Lin C.C., Yang J.S., Chen J.T., Fan S., Yu F.S., Yang J.L., Lu C.C., Kao M.C., Huang A.C., Lu H.F., and Chung J.G. Berberine induces apoptosis in human HSC-3 oral cancer cells via simultaneous activation of the death receptor-mediated and mitochondrial pathway. Anticancer Research 27 (2007) 3371-3378
22. Lee S., Lim H.J., Park H.Y., Lee K.S., Park J.H., and Jang Y. Berberine inhibits rat vascular smooth muscle cell proliferation and migration in vitro and improves neointima formation after balloon injury in vivo. Berberine improves neointima formation in a rat model. Atherosclerosis 186 (2006) 29-37
23. Hsu S.C., Kuo C.L., Lin J.P., Lee J.H., Lin C.C., Su C.C., Yang M.D., and Chung J.G. Crude extracts of Euchresta formosana radix inhibit invasion and migration of human hepatocellular carcinoma cells. Anticancer Research 27 (2007) 2377-2384
24. Lee J.H., Li Y.C., Ip S.W., Hsu S.C., Chang N.W., Tang N.Y., Yu C.S., Chou S.T., Lin S.S., Lino C.C., Yang J.S., and Chung J.G. The role of Ca2+ in baicalein-induced apoptosis in human breast MDA-MB-231 cancer cells through mitochondria- and caspase-3-dependent pathway. Anticancer Research 28 (2008) 1701-1711
25. Huang Y.T., Hwang J.J., Lee L.T., Liebow C., Lee P.P., Ke F.C., Lo T.B., Schally A.V., and Lee M.T. Inhibitory effects of a luteinizing hormone-releasing hormone agonist on basal and epidermal growth factor-induced cell proliferation and metastasis-associated properties in human epidermoid carcinoma A431 cells. International Journal of Cancer 99 (2002) 505-513
26. Mantena S.K., Sharma S.D., and Katiyar S.K. Berberine, a natural product, induces G1-phase cell cycle arrest and caspase-3-dependent apoptosis in human prostate carcinoma cells. Molecular Cancer Therapeutics 5 (2006) 296-308
27. Nakano H., Shindo M., Sakon S., Nishinaka S., Mihara M., Yagita H., and Okumura K. Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proceedings of the National Academy of Sciences of the United States of America 95 (1998) 3537-3542
28. Orlowski R.Z., and Baldwin Jr. A.S. NF-kappaB as a therapeutic target in cancer. Trends in Molecular Medicine 8 (2002) 385-389
29. Pandey M.K., Sung B., Kunnumakkara A.B., Sethi G., Chaturvedi M.M., and Aggarwal B.B. Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Research 68 (2008) 5370-5379
30. Yi P., Lu F.E., Xu L.J., Chen G., Dong H., and Wang K.F. Berberine reverses free-fatty-acid-induced insulin resistance in 3T3-L1 adipocytes through targeting IKKbeta. World Journal of Gastroenterology 14 (2008) 876-883
31. Hu J.P., Nishishita K., Sakai E., Yoshida H., Kato Y., Tsukuba T., and Okamoto K. Berberine inhibits RANKL-induced osteoclast formation and survival through suppressing the NF-kappaB and Akt pathways. European Journal of Pharmacology 580 (2008) 70-79
32. Enk R., Ehehalt R., Graham J.E., Bierhaus A., Remppis A., and Greten H.J. Differential effect of Rhizoma coptidis and its main alkaloid compound berberine on TNF-alpha induced NFkappaB translocation in human keratinocytes. Journal of Ethnopharmacology 109 (2007) 170-175
33. Woessner Jr. J.F., and Gunja-Smith Z. Role of metalloproteinases in human osteoarthritis. The Journal of Rheumatology 27 (1991) 99-101
34. Ray J.M., and Stetler-Stevenson W.G. The role of matrix metalloproteases and their inhibitors in tumour invasion, metastasis and angiogenesis. European Respiratory Journal 7 (1994) 2062-2072
35. Stetler-Stevenson W.G. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. The Journal of Clinical Investigation 103 (1999) 1237-1241
36. Stallings-Mann M., and Radisky D. Matrix metalloproteinase-induced malignancy in mammary epithelial cells. Cells, Tissues, Organs 185 (2007) 104-110
37. Wang M., Wang T., Liu S., Yoshida D., and Teramoto A. The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades. Brain Tumor Pathology 20 (2003) 65-72
38. Komatsu K., Nakanishi Y., Nemoto N., Hori T., Sawada T., and Kobayashi M. Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas. Brain Tumor Pathology 21 (2004) 105-112
39. Stetler-Stevenson W.G. Type IV collagenases in tumor invasion and metastasis. Cancer Metastasis Reviews 9 (1990) 289-303
40. Giancotti F.G., and Ruoslahti E. Integrin signaling. Science 285 (1999) 1028-1032 New York, NY
41. Zeng Z.S., Cohen A.M., and Guillem J.G. Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis 20 (1999) 749-755
42. Bianco Jr. F.J., Gervasi D.C., Tiguert R., Grignon D.J., Pontes J.E., Crissman J.D., Fridman R., and Wood Jr. D.P. Matrix metalloproteinase-9 expression in bladder washes from bladder cancer patients predicts pathological stage and grade. Clinical Cancer Research 4 (1998) 3011-3016
43. Cockett M.I., Murphy G., Birch M.L., O'Connell J.P., Crabbe T., Millican A.T., Hart I.R., and Docherty A.J. Matrix metalloproteinases and metastatic cancer. Biochemical Society Symposium 63 (1998) 295-313
44. Papathoma A.S., Zoumpourlis V., Balmain A., and Pintzas A. Role of matrix metalloproteinase-9 in progression of mouse skin carcinogenesis. Molecular Carcinogenesis 31 (2001) 74-82
45. Murphy A.N., Unsworth E.J., and Stetler-Stevenson W.G. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. Journal of Cellular Physiology 157 (1993) 351-358
46. Benelli R., Adatia R., Ensoli B., Stetler-Stevenson W.G., Santi L., and Albini A. Inhibition of AIDS-Kaposi's sarcoma cell induced endothelial cell invasion by TIMP-2 and a synthetic peptide from the metalloproteinase propeptide: implications for an anti-angiogenic therapy. Oncology Research 6 (1994) 251-257
47. Bond M., Fabunmi R.P., Baker A.H., and Newby A.C. Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kappa B. FEBS Letters 435 (1998) 29-34
48. Farina A.R., Tacconelli A., Vacca A., Maroder M., Gulino A., and Mackay A.R. Transcriptional up-regulation of matrix metalloproteinase-9 expression during spontaneous epithelial to neuroblast phenotype conversion by SK-N-SH neuroblastoma cells, involved in enhanced invasivity, depends upon GT-box and nuclear factor kappaB elements. Cell Growth Differentiation 10 (1999) 353-367
49. Lin T.H., Kuo H.C., Chou F.P., and Lu F.J. Berberine enhances inhibition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide. BMC Cancer 8 (2008) 58
50. Wartenberg M., Budde P., De Marees M., Grunheck F., Tsang S.Y., Huang Y., Chen Z.Y., Hescheler J., and Sauer H. Inhibition of tumor-induced angiogenesis and matrix-metalloproteinase expression in confrontation cultures of embryoid bodies and tumor spheroids by plant ingredients used in traditional chinese medicine. Laboratory Investigation 83 (2003) 87-98
51. Lee S.J., Sakurai H., Oshima K., Kim S.H., and Saiki I. Anti-metastatic and anti-angiogenic activities of a new matrix metalloproteinase inhibitor, TN-6b. European Journal of Cancer 39 (2003) 1632-1641
52. Naglich J.G., Jure-Kunkel M., Gupta E., Fargnoli J., Henderson A.J., Lewin A.C., Talbott R., Baxter A., Bird J., Savopoulos R., Wills R., Kramer R.A., and Trail P.A. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Research 61 (2001) 8480-8485
53. Mackay A.R., Corbitt R.H., Hartzler J.L., and Thorgeirsson U.P. Basement membrane type IV collagen degradation: evidence for the involvement of a proteolytic cascade independent of metalloproteinases. Cancer Research 50 (1990) 5997-6001
54. Aguirre Ghiso J.A., Alonso D.F., Farias E.F., Gomez D.E., and de Kier Joffe E.B. Deregulation of the signaling pathways controlling urokinase production. Its relationship with the invasive phenotype. European Journal Biochemistry 263 (1999) 295-304
55. Shi Z., and Stack M.S. Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity. Biochemical Journal 407 (2007) 153-159
56. Baker E.A., Leaper D.J., Hayter J.P., and Dickenson A.J. Plasminogen activator system in oral squamous cell carcinoma. British Journal of Oral & Maxillofacial Surgery 45 (2007) 623-627
57. Sliva D. Signaling pathways responsible for cancer cell invasion as targets for cancer therapy. Current Cancer Drug Targets 4 (2004) 327-336
58. Shishodia S., Potdar P., Gairola C.G., and Aggarwal B.B. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 24 (2003) 1269-1279
59. Hidalgo M., and Eckhardt S.G. Development of matrix metalloproteinase inhibitors in cancer therapy. Journal of the National Cancer Institute 93 (2001) 178-193